PharmiWeb6d
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab ... and cemiplimab could offer a new standard of care for patients in Scotland who ...
PharmaTimes5d
Libtayo available in Scotland for cervical cancer patients
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab ... This open-label multi-centre randomised trial included patients with disease ...
News Medical on MSN1d
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
pharmaphorum3d
EC approves Regeneron's Libtayo for advanced cervical cancer
Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...
pharmaphorum1d
Sanofi and Regeneron eye Libtayo challenge to Keytruda in first-line lung cancer
Now, Libtayo (cemiplimab) is also in the mix. Sanofi and Regeneron have just halted a 466-patient phase 3 trial of the drug in combination with chemo rarely, saying they saw a significant ...
The Globe and Mail4d
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients ... therapies for cancer patients, today announced a clinical supply agreement with Regeneron Pharmaceuticals ...
Yahoo Finance4d
Regeneron Announces Investor Conference Presentations
Regeneron (NASDAQ: REGN ... Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases ...
Nasdaq4d
Regeneron Pharmaceuticals' Linvoseltamab BLA Resubmission Accepted by FDA for Review in Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for linvoseltamab, an investigational treatment for adult patients with ...
Cure Today6d
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
Treatment with the lead clinical candidate THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) sequenced with the checkpoint inhibitor Libtayo (cemiplimab) extended overall survival (OS) in patients with ...
Nasdaq4d
Regeneron Pharma Says FDA Accepted BLA For Linvoseltamab To Treat Multiple Myeloma
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Tuesday said that the resubmission of Biologics License Application (BLA) for linvoseltamab for the treatment of multiple myeloma has been ...
Yahoo Finance3d
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who ...
Morningstar4d
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
At Regeneron, we’re applying more than three decades of biology expertise with our proprietary VelociSuite® technologies to develop medicines for patients with diverse blood cancers and rare ...